Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOFLAME-19
2022-001682-12Phase 3Active
- Sponsor
- Goethe University Frankfurt
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of losartan and prednisolone in cardiovascular inflammatory disorders and myocarditis (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Absolute change in left ventricular ejection fraction. Started Dec 2022; status: active.
02
Drugs
losartanprednisolone
03
Conditions
cardiovascular inflammatory disordersmyocarditis
Beyond the preview
Go deeper on 2022-001682-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001682-12.